Logo

Daiichi Sankyo and AstraZeneca Entered into a Second Clinical Trial Collaboration with Merck for Datopotamab Deruxtecan (Dato-DXd) + Keytruda (pembrolizumab)

Share this
Daiichi Sankyo and AstraZeneca Entered into a Second Clinical Trial Collaboration with Merck for Datopotamab Deruxtecan (Dato-DXd) + Keytruda (pembrolizumab)

Tuba Khan

Daiichi Sankyo and AstraZeneca Entered into a Second Clinical Trial Collaboration with Merck for Datopotamab Deruxtecan (Dato-DXd) + Keytruda (pembrolizumab)

Shots:

  • The companies collaborated to evaluate datopotamab deruxtecan + Keytruda vs Keytruda alone in P-III TROPION-Lung08 trial in ~740 patients with PD-L1 high advanced or metastatic NSCLC without actionable genomic alterations over multiple sites in Asia- EU- North & South America
  • The 1EPs of a trial are PFS & OS. Additionally- the second clinical trial collaboration is based on the results in an ongoing P-Ib study
  • In Jul’20- Daiichi Sankyo has entered into a collaboration with AstraZeneca to develop and commercialize datopotamab deruxtecan except in Japan. Daiichi Sankyo maintains exclusive rights  & is responsible for the manufacturing & supply of datopotamab deruxtecan

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Medical Dialogues

Click Here

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family